RSS

Verseon

Technology-based pharma company, Verseon, has submitted a Phase I clinical trial protocol for its lead precision oral anticoagulant (PROAC) — VE-1902 — to the Bellberry Human Research Ethics Committee (HREC) in Australia. more

Technology

Verseon presents further trial data on the low bleeding risk of its family of preclinical anti-coagulant drugs at BioEurope conference more

News